Background A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early …

Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for
medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or …

Background Clinical decision-making for patients with stage I lung cancer is complex. It
involves multiple options [lobectomy, segmentectomy, wedge, stereotactic body …

Lung cancer remains the leading cause of cancer deaths in the United States (US) and
worldwide. Radiation therapy is a mainstay in the treatment of locally advanced non-small …

Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-
early-stage non-small cell lung cancer (NSCLC). One third of patients progress and …

Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-
based guideline on treatment with stereotactic body radiotherapy (SBRT) for patients with …

Purpose Stereotactic body radiation therapy (SBRT) for≥ 5 cm lesions is poorly defined,
largely owing to the low sample sizes in existing studies. The present analysis examined the …

The standard-of-care treatment for early-stage non-small cell lung cancer (NSCLC)
continues to be surgery in the form of lobectomy or pneumonectomy. Stereotactic body …

Background Contrary to prevailing notions of uniform efficacy regarding stereotactic body
radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC), a recent report …

Lung cancer is the second most common cancer in men and women in the United States
and the leading cause of cancer death in both sexes. 1 Non–small cell histology represents …